In 2018, the American Academy of Orthopaedic Surgeons (AAOS) launched a registry feasibility pilot with guidance from the Musculoskeletal Tumor Society (MSTS). The Musculoskeletal Tumor Registry (MsTR) pilot began capturing data on orthopaedic oncology bone tumor procedures in a structured and scalable way. The decision was made to broaden the MsTR program from a pilot to a full registry at the end of 2019. The MsTR is the third subspecialty registry to be incorporated into the AAOS family of registries.
The wide-spread rollout of the MsTR allows surgeons to combine data about rare bone and soft tissue tumors from institutions around the country, thereby potentially answering treatment and outcome questions that are otherwise unable to be answered due to the rarity of the disease. The MsTR dashboards will help clinicians and health systems track function, complications, and outcomes in patients treated for these sarcomas with the potential to expand to other musculoskeletal tumors and metastatic bone diseases in the future.
For more information about MsTR data elements, the data submission process, and participation benefits, visit the AAOS website.